Cidara Therapeutics, Inc. (CDTX) is a publicly traded Healthcare sector company. As of May 20, 2026, CDTX trades at $221.38 with a market cap of $6.96B and a P/E ratio of -8.28. CDTX moved +0.03% today. Year to date, CDTX is +228.02%; over the trailing twelve months it is +731.63%. Its 52-week range spans $10.14 to $221.42. Analyst consensus is buy with an average price target of $221.50. Rallies surfaces CDTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cidara Therapeutics, Inc. (CDTX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. CDTX moved +0.03% today. Analyst consensus is buy.
| Metric | Value |
|---|---|
| Price | $221.38 |
| Market Cap | $6.96B |
| P/E Ratio | -8.28 |
| EPS | $-26.75 |
| Dividend Yield | 0.00% |
| 52-Week High | $221.42 |
| 52-Week Low | $10.14 |
| Volume | 2.69M |
| Avg Volume | 0 |
| Revenue (TTM) | $1.27M |
| Net Income | $-169.83M |
| Gross Margin | 0.00% |
11 analysts cover CDTX: 1 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $221.50.